Detection of antibody–drug conjugate-induced interstitial lung disease using circulating cell-free DNA
This proof-of-concept study demonstrates that liquid biopsy can be developed as a valuable tool for detecting and monitoring ADC-related ILD. Its low cost and simplicity make it a potential alternative to current imaging methods, warranting further clinical development.
Authors
- Albert Grinshpun (ORCID: https://orcid.org/0000-0002-3351-5719)
- Sara M. Tolaney (ORCID: https://orcid.org/0000-0002-5940-8671)
- Aviad Zick (ORCID: https://orcid.org/0000-0002-5077-9249)
- Judith Magenheim (ORCID: https://orcid.org/0000-0003-3969-0662)
- Tamar Perri (ORCID: https://orcid.org/0000-0002-4042-6554)
- Ori Fridlich
- Paolo Tarantino (ORCID: https://orcid.org/0000-0001-8686-0228)
- A. Naim
Institutions
- Hebrew University of Jerusalem (IL)
- Hadassah Medical Center (IL)
- University Medical Center (US)
- Concern Foundation (US)
- Dana-Farber Cancer Institute (US)
- Dana-Farber/Harvard Cancer Center (US)
- Dana-Farber Brigham Cancer Center (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103715
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Exelixis
- Eisai
- Genentech
- Daiichi Sankyo Europe